Yes. Thanks, David.
First, pricing else XX,XXX $X.X little a to billion visibility or certainly revenue. any as what – about so think will anyone and that, patients in represents the recognize of do approximately marketplace, over over having not we we
quite patient, $XXX,XXX on So, of to per per running expensive is per the patient $XXX,XXX price north average. year obviously
in we you of think So, as have others, we an when about generic authorized think then window, and about through XXXX done are with kind our the payers XXXX scenario. pricing and research as we
compression, as that the you come is you generics will in will when rate expectation some XXXX. at you see that see will think likely multiple but I price same the obviously not
do won’t and place for to that bring to create will, XXXX around what to position the you our we opportunities to have appropriately now believe if rightful the From us product give opportunity an version between Jazz in that that priced marketplace. low a is view, their opportunity market to we could or fully that that end sodium an us will excess of FTXXX standpoint, be understanding
so, we be kick even do be it’s – are generic current that our quantity relative to do when settlements based think in and will do scrutinized right. say do. heavily prior authorizations, to think believe Right, in, – we the step that we that and more edits, broader compression that step the necessity, products some limits edits additional these I price research upon could we today XXXX But fair medical authorized there
see this molecule role the for So, dramatically will for is in third-line part the is future that a we in always a oxybate sodium change nor be do typically most this changing to polypharmacy as we that category going product there either, and the don’t marketplace. in think
It’s our through sodium to from strategies, commercially and that a and take market oxybate commercial job standpoint strategies, focus an strategies. pricing is of the XXX% our both share market execution access distribution
again, and won’t As to won’t is, generally, or stays litigations it right. can’t whether as XX-months what litigate, statute, speak or relates we not the David and we will Jazz to to just speak
as match in not not as XXX as to that label and commentary NDA will (b)(X) an reference does noted our a the So, twice-nightly listed drug that oxybate. we of sodium the
to data Orange we relates Book upon that based us believe are patents. it that options which statute inform says, done already going as what discuss and to listed relevant to data there effectively strategy that are generate the we’ve labeling will the our not We for
the those then, then right, successful based statute, required patents should are Hatch upon be in if certify in a be in listed position a Book else stay, we nor XX-months position enforce will Orange we Waxman. ourselves labeling will anyone to in find position appropriately addressing where a a And our essence to or Jazz per in
parties that intellectual don’t assert have choose to themselves. It they doesn’t property that mean
and confident strategies our successful clinical or feel that prevail very from we a labeling if litigation of However, we regulatory are in our Hatch probability outside Waxman to standpoint. likelihood that and even
it. We confident feel in very
– from the that we’ve We’ve and leading advice and dataset. executed experts we So we’ve clear got for us what it’s employed. strategy very we our know great
yet to path. with that patents. on this effectively at But for is we pursuing disclose the listed data are Orange there reason stage to deal Book have we a address we and pathway that feel and clear us no So,
clear, not we an And to stay are be is NDA. issue a XX-months an because automatic again, here,
those does Book it will label that relates not and and and patents. how listed match understand not be there to match Our around as differences manifest Orange we differences their themselves will respective
